MedTrace Logo

Bioavailability Study of 2 Oral Formulations of ALXN1840

NCT04610580 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-01-16

Study results available
· View outcomes & findings →

Summary

The study will assess the relative bioavailability of 2 different formulations of ALXN1840 in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

ALXN1840

ALXN1840 will be administered orally.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Eugene S. Swenson, MD, PhD · Alexion Pharmaceuticals, Inc.

  • Masood Sadaat, MD, MSc · Alexion Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2021-03-24
Completion
2021-04-26
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04610580 on ClinicalTrials.gov